Breakthrough Drug Shows Promise in Treating Hormone-Related Hypertension
A groundbreaking clinical trial introduces Baxdrostat, a novel medication showing significant promise in treating hormone-driven high blood pressure, potentially offering a long-term cure for primary aldosteronism.
Researchers led by Professor Morris Brown FRS at Queen Mary University of London have discovered a promising new treatment for primary aldosteronism, a condition characterized by excessive production of the hormone aldosterone by the adrenal glands. This hormone regulates sodium and potassium levels in the blood and, when overproduced, leads to high blood pressure that is often difficult to control with standard medications.
The new medication, Baxdrostat, belongs to a novel class called aldosterone synthase inhibitors. During the phase 2a clinical trial, 15 patients with confirmed primary aldosteronism and resistant hypertension received Baxdrostat treatment. The drug was administered over 72 weeks with dosage adjustments and was generally well tolerated, except at the highest doses. Notably, Baxdrostat reduced aldosterone levels by about 90% and restored potassium balance, which is commonly disrupted in primary aldosteronism.
Remarkably, some patients maintained normal blood pressure and hormone levels even after stopping the drug, indicating potential for long-term remission or cure—an outcome previously achievable only through surgery or thermal therapy.
The findings were published in the New England Journal of Medicine and announced at ENDO 2025 in San Francisco. These promising results suggest that Baxdrostat could be a safe, effective, and non-invasive treatment option, helping to address the significant underdiagnosis of primary aldosteronism, which accounts for roughly 10% of hypertension cases.
According to Professor Brown, this development could encourage more doctors to test for this condition, especially in cases of difficult-to-control blood pressure. Experts like Dr. Mason Freeman of Harvard Medical School agree that these results mark a pivotal step toward targeting the biological root of primary aldosteronism. Larger clinical trials are now underway, aiming for regulatory approval within the next few years, offering hope for many patients worldwide.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Promising Advances in HIV Vaccine Development Demonstrate Pathway to Broadly Neutralizing Antibodies
Recent phase 1 trials reveal promising vaccine strategies that activate immune responses targeting diverse HIV strains, bringing us closer to an effective HIV vaccine using innovative mRNA technology.
FDA Issues Safety Warnings on Boston Scientific Heart Devices Linked to Injuries and Fatalities
The FDA has issued safety warnings on Boston Scientific heart devices, alerting healthcare providers and patients about risks of device failure, injuries, and deaths associated with defibrillator wires and the Watchman stroke prevention device.
Experts Warn: Chemical Pesticides May Elevate Foodborne Illness Risks
Research indicates that the use of chemical pesticides in farming may increase the risk of foodborne illnesses, prompting calls for natural alternatives and regenerative agriculture practices. Experts highlight growing food recalls due to contamination and emphasize consumer choices for safer, sustainably farmed foods.